查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878947

核酸療法CDMO市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、服務、應用、地區和競爭格局分類，2020-2030年預測

Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Service, by Application, by region, and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球核酸療法CDMO市場規模為115.2億美元，預計2030年將以8.29%的複合年成長率成長至185.8億美元。核酸療法是一類獨特的藥物，利用DNA或RNA等遺傳物質來調節基因表達，以達到治療目的，涵蓋反義寡核苷酸、小干擾RNA和信使RNA等多種療法。全球核酸療法合約開發與生產組織（CDMO）市場的主要驅動力是生物製藥研發投入的增加、新型核酸藥物候選產品管線的不斷擴充以及對專業生產能力的迫切需求。

市場概覽
預測期 2026-2030
2024年市場規模 115.2億美元
2030年市場規模 185.8億美元
2025-2030年複合年成長率 8.29%
成長最快的細分市場 基於RNA的療法
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球核酸療法CDMO市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（基因療法、RNA療法）
    • 依服務類型（製程開發與最佳化、製造服務、分析與品質控制服務、其他）
    • 依應用領域（腫瘤學、遺傳性疾病、傳染病、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美核酸療法CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲核酸療法CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區核酸療法CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲核酸療法CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲核酸療法CDMO市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球核酸治療藥物CDMO市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Catalent Inc.
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Genomics
  • Sirion Biotech GmbH
  • Oxford Biomedica Plc.
  • Danaher Corp.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20931

The Global Nucleic Acid Therapeutics CDMO Market, valued at USD 11.52 Billion in 2024, is projected to experience a CAGR of 8.29% to reach USD 18.58 Billion by 2030. Nucleic acid therapeutics represent a distinct class of pharmaceutical products utilizing genetic material, such as DNA or RNA, to modulate gene expression for therapeutic purposes, encompassing modalities like antisense oligonucleotides, small interfering RNAs, and messenger RNAs. The global Contract Development and Manufacturing Organization (CDMO) market for these therapeutics is primarily driven by expanding biopharmaceutical research and development investments, the increasing pipeline of novel nucleic acid drug candidates, and the critical need for specialized manufacturing capabilities.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.52 Billion
Market Size 2030USD 18.58 Billion
CAGR 2025-20308.29%
Fastest Growing SegmentRNA-based Therapies
Largest MarketNorth America

Key Market Drivers

The expanding therapeutic pipeline for nucleic acid modalities significantly underpins the growth of the Contract Development and Manufacturing Organization market. The increasing number of novel drug candidates, including antisense oligonucleotides, messenger RNAs, and small interfering RNAs, necessitates specialized expertise and infrastructure for their development and large-scale production. These modalities offer targeted approaches for previously intractable diseases, creating a robust demand for outsourced services. For example, according to the article "Advancements in clinical RNA therapeutics: Present developments and prospective outlooks" published in PMC in April 2024, the exploration of antisense oligonucleotide-based therapies alone has progressed through 100 Phase I trials, with 25% of these advancing to Phase II or III trials, indicating a substantial volume of candidates requiring further development and manufacturing support. This progression through clinical stages directly translates into a requirement for advanced process development, analytical testing, and Good Manufacturing Practice compliant production.

Key Market Challenges

The inherent complexity and scalability issues associated with manufacturing advanced nucleic acid therapeutics, particularly in consistently achieving required quality and purity standards at commercial production volumes, represent a significant impedance to the growth of the global Contract Development and Manufacturing Organization (CDMO) market. These modalities often require specialized equipment, highly controlled environments, and intricate purification processes, leading to elevated operational costs and extended development timelines for CDMOs. Such manufacturing intricacies limit the capacity of CDMOs to efficiently process the increasing pipeline of novel drug candidates, creating bottlenecks within the supply chain.

Key Market Trends

Strategic Capacity Expansion Initiatives represent a significant trend as Contract Development and Manufacturing Organizations invest heavily to meet the escalating demand for nucleic acid therapeutics. This involves constructing new facilities, expanding existing operational footprints, and integrating advanced equipment to enhance overall manufacturing throughput and capabilities. Such proactive investments are crucial for ensuring the reliable and timely supply of critical drug substances and products, thereby supporting the clinical and commercial progression of novel therapies. For instance, according to a BioSpace report in January 2024, Lonza projected flat sales for the year but confirmed mid-term guidance and reported full-year 2023 sales of $7.75 billion, driven by strong performance in its Biologics and Small Molecules divisions, highlighting sustained investment in its manufacturing network. In October 2024, Lonza also completed the acquisition of a large-scale biologics facility in Vacaville, US, from Roche, further expanding its capabilities and dedicating CHF 1.4 billion of CapEx in 2024 towards its organic investment program for future growth across technologies.

Key Market Players

  • Catalent Inc.
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Genomics
  • Sirion Biotech GmbH
  • Oxford Biomedica Plc.
  • Danaher Corp.

Report Scope:

In this report, the Global Nucleic Acid Therapeutics CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nucleic Acid Therapeutics CDMO Market, By Type:

  • Gene Therapy
  • RNA-based Therapies

Nucleic Acid Therapeutics CDMO Market, By Service:

  • Process Development & Optimization
  • Manufacturing Services
  • Analytical and Quality Control Services
  • Others

Nucleic Acid Therapeutics CDMO Market, By Application:

  • Oncology
  • Genetic Disorders
  • Infectious Diseases
  • Others

Nucleic Acid Therapeutics CDMO Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Nucleic Acid Therapeutics CDMO Market.

Available Customizations:

Global Nucleic Acid Therapeutics CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nucleic Acid Therapeutics CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Gene Therapy, RNA-based Therapies)
    • 5.2.2. By Service (Process Development & Optimization, Manufacturing Services, Analytical and Quality Control Services, Others)
    • 5.2.3. By Application (Oncology, Genetic Disorders, Infectious Diseases, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Nucleic Acid Therapeutics CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Service
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Nucleic Acid Therapeutics CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Service
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Nucleic Acid Therapeutics CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Service
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Nucleic Acid Therapeutics CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Service
        • 6.3.3.2.3. By Application

7. Europe Nucleic Acid Therapeutics CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Service
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Nucleic Acid Therapeutics CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Service
        • 7.3.1.2.3. By Application
    • 7.3.2. France Nucleic Acid Therapeutics CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Service
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Nucleic Acid Therapeutics CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Service
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Nucleic Acid Therapeutics CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Service
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Nucleic Acid Therapeutics CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Service
        • 7.3.5.2.3. By Application

8. Asia Pacific Nucleic Acid Therapeutics CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Service
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Nucleic Acid Therapeutics CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Service
        • 8.3.1.2.3. By Application
    • 8.3.2. India Nucleic Acid Therapeutics CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Service
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Nucleic Acid Therapeutics CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Service
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Nucleic Acid Therapeutics CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Service
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Nucleic Acid Therapeutics CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Service
        • 8.3.5.2.3. By Application

9. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Service
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Nucleic Acid Therapeutics CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Service
        • 9.3.1.2.3. By Application
    • 9.3.2. UAE Nucleic Acid Therapeutics CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Service
        • 9.3.2.2.3. By Application
    • 9.3.3. South Africa Nucleic Acid Therapeutics CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Service
        • 9.3.3.2.3. By Application

10. South America Nucleic Acid Therapeutics CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Service
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nucleic Acid Therapeutics CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Service
        • 10.3.1.2.3. By Application
    • 10.3.2. Colombia Nucleic Acid Therapeutics CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Service
        • 10.3.2.2.3. By Application
    • 10.3.3. Argentina Nucleic Acid Therapeutics CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Service
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Nucleic Acid Therapeutics CDMO Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Catalent Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Lonza Group Ltd.
  • 15.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 15.5. Charles River Laboratories International, Inc.
  • 15.6. Eurofins Genomics
  • 15.7. Sirion Biotech GmbH
  • 15.8. Oxford Biomedica Plc.
  • 15.9. Danaher Corp.

16. Strategic Recommendations

17. About Us & Disclaimer